Wockhardt Ltd.

Wockhardt's Q3 profit after tax surged threefold to Rs 61 crore. Revenue rose to Rs 888 crore. Upcoming insulin analogs launch is a key opportunity.

Delius Pharma gets CDSCO approval to import Ceftriaxone Sodium API from China. Enhances supply, ensures quality, reduces dependency.

Wockhardt receives NDA status from US FDA for its novel antibiotic Zaynich, a first for an Indian pharma company. Shares surge on the BSE.

Wockhardt reports Rs 82 crore profit in Q2, ending Sept 30, 2025. Revenue declines to Rs 782 crore. India, UK, and Ireland business growth detailed.

Indian investments in the UK to generate 6,900 new jobs across various sectors. UK-India trade deal boosts investor confidence.

India asserts its support for auto & renewable energy complies with WTO norms, vowing to defend them against China's challenge.

Coal India arm SECL identifies 7 mine dumps for rare earth exploration. Tendering underway for scientific assessment.

Rupee gains against the US dollar in early trade. Factors include weaker greenback, strong equities, crude oil prices, & FII outflows.

Sensex and Nifty rebound in early trade, driven by IT stocks and positive global cues. Key gainers and losers, FII/DII activity.

Rajiv Bajaj criticizes Maharashtra's EV policy, Aaditya Thackeray blames BJP for its collapse. Subsidies slowed dramatically.

India asserts its support for auto & renewable energy complies with WTO norms, vowing to defend them against China's challenge.

Coal India arm SECL identifies 7 mine dumps for rare earth exploration. Tendering underway for scientific assessment.

AISEF and ESA sign MoU to strengthen India-EU spice trade cooperation on food safety, sustainability, and regulatory alignment.

Rupee gains against the US dollar in early trade. Factors include weaker greenback, strong equities, crude oil prices, & FII outflows.

Sensex and Nifty rebound in early trade, driven by IT stocks and positive global cues. Key gainers and losers, FII/DII activity.